PMC:7408073 / 98743-99143 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"3451","span":{"begin":116,"end":120},"obj":"Gene"},{"id":"3452","span":{"begin":220,"end":224},"obj":"Gene"},{"id":"3453","span":{"begin":324,"end":330},"obj":"Species"}],"attributes":[{"id":"A3451","pred":"tao:has_database_id","subj":"3451","obj":"Gene:59272"},{"id":"A3452","pred":"tao:has_database_id","subj":"3452","obj":"Gene:59272"},{"id":"A3453","pred":"tao:has_database_id","subj":"3453","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"No significant adverse effects were described upon its chronic administration neither alone nor in combination with ACE2 activators (while inhibiting their activating effects) nor after inducing functional impairment of ACE2 activity in rodent experiments in vivo [52,117,118,122,183,184] nor in a clinical Phase I trial in humans (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf);"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1207","span":{"begin":121,"end":131},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1208","span":{"begin":156,"end":166},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1209","span":{"begin":225,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1210","span":{"begin":296,"end":297},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1211","span":{"begin":324,"end":330},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"No significant adverse effects were described upon its chronic administration neither alone nor in combination with ACE2 activators (while inhibiting their activating effects) nor after inducing functional impairment of ACE2 activity in rodent experiments in vivo [52,117,118,122,183,184] nor in a clinical Phase I trial in humans (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf);"}

{"project":"2_test","denotations":[{"id":"32708755-20797602-20679024","span":{"begin":265,"end":267},"obj":"20797602"},{"id":"32708755-18235039-20679025","span":{"begin":268,"end":271},"obj":"18235039"},{"id":"32708755-20300067-20679026","span":{"begin":272,"end":275},"obj":"20300067"},{"id":"32708755-19517214-20679027","span":{"begin":276,"end":279},"obj":"19517214"},{"id":"32708755-23370913-20679028","span":{"begin":280,"end":283},"obj":"23370913"},{"id":"32708755-31982938-20679029","span":{"begin":284,"end":287},"obj":"31982938"}],"text":"No significant adverse effects were described upon its chronic administration neither alone nor in combination with ACE2 activators (while inhibiting their activating effects) nor after inducing functional impairment of ACE2 activity in rodent experiments in vivo [52,117,118,122,183,184] nor in a clinical Phase I trial in humans (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf);"}